Ozgur Mehtap
Overview
Explore the profile of Ozgur Mehtap including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atas U, Salim O, Iltar U, Yucel O, Kucukdiler Eroglu A, Aslan V, et al.
Turk J Haematol
. 2024 Nov;
41(4):225-235.
PMID: 39501735
Objective: In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma...
2.
Mehtap O, Toptas T, Dal M, Keklik Karadag F, Atas U, Ozsan G, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2190-2198.
PMID: 39269267
Predictive prognostic scoring (PS) systems are not primarily applicable to elderly patients with classical Hodgkin lymphoma (cHL). The objective of this study was to develop a PS system for these...
3.
Merryman R, Mehtap O, LaCasce A
Turk J Haematol
. 2024 Apr;
41(2):69-82.
PMID: 38660754
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma in Western countries. While FL is generally incurable, standard initial therapies are associated with high response rates and...
4.
Yigit Kaya S, Mutlu Y, Malkan U, Mehtap O, Keklik Karadag F, Korkmaz G, et al.
Leuk Res
. 2024 Apr;
140:107495.
PMID: 38599153
Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies....
5.
Geduk A, Polat M, Terzi Demirsoy E, Oztas B, Eryilmaz B, Yenihayat E, et al.
Turk J Haematol
. 2024 Mar;
41(2):83-90.
PMID: 38426298
Objective: Calprotectin (CLP), S100A6, and high mobility group nucleosome-binding protein 1 (HMGN1), known as alarmins, are involved in the pathogenesis of many tumors. In this study, we aimed to investigate...
6.
Geduk A, Oztas B, Eryilmaz B, Terzi Demirsoy E, Menguc M, Unal S, et al.
Indian J Hematol Blood Transfus
. 2023 Jun;
39(3):518.
PMID: 37304480
[This corrects the article DOI: 10.1007/s12288-022-01574-6.].
7.
Demirci U, Kurt Yuksel M, Kirkizlar H, Birtas Atesoglu E, Mehtap O, Salim O, et al.
Blood Res
. 2023 Jun;
58(2):99-104.
PMID: 37292008
Background: Central nervous system (CNS) prophylactic options for diffuse large B-cell lymphoma (DLBCL) are administered differently in most centers. Unfortunately, there is still not a consensus on which patients, which...
8.
Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal M, et al.
Hematol Oncol
. 2023 May;
41(4):663-673.
PMID: 37211991
Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal...
9.
Geduk A, Oztas B, Eryilmaz B, Terzi Demirsoy E, Menguc M, Unal S, et al.
Indian J Hematol Blood Transfus
. 2023 Apr;
39(2):220-227.
PMID: 37006982
Purpose: The receptor for advanced glycation end products (RAGE) upregulated during the onset and progression of cancer and bone-related pathologies. In this study, we aimed to investigate the role of...
10.
Dal M, Ulu B, Uzay A, Akay O, Besisik S, Yenerel M, et al.
Ann Hematol
. 2022 Nov;
102(1):133-140.
PMID: 36401621
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL...